Immunosuppression - An overview

Seminars in Veterinary Medicine and Surgery-Small Animal

Volumn 12, Issue 3, 1997, Pages 144-149

  Miller, Ellen ^a,b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ANIMAL DISEASE; CAT; CAT DISEASE; DOG; DOG DISEASE; DRUG EFFECT; IMMUNE SYSTEM; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; REVIEW;

ANIMALS; CAT DISEASES; CATS; DOG DISEASES; DOGS; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS;

EID: 0031204731     PISSN: 08820511     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-2867(97)80025-4     Document Type: Article

References (43)

1. Miescher P, Beris P: Immunosuppressive therapy in the treatment of autoimmune diseases. Springer Semin Immunopathol 7:69-90, 1984
2. Klag AR, Giger U, Shofer FS: Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). JAVMA 5:783-788, 1993
3. Scott DW, Walton DK, Manning TO, et al: Canine lupus erythematosus. I. Systemic lupus erythematosus. JAAHA 19:461-479, 1983
4. Paliogianni F, Ahuja SS, Balow JP, et al: Novel mechanism for inhibition of human T cells by glucocorticoids. J Immunol 151:4081-4089, 1993
5. Arya SK, Wong-Staal F, Gallo RC: Dexamethasone mediated inhibition of T cell growth factor and gamma interferon messenger RNA. J Immunol 133:273, 1984
6. Boumpas DT, Anastassiou ED, Older SA, et al: Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J Clin Invest 87:1739, 1991
7. Pagliogianni F, Raptis A, Ahuja SS, et al: Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NFAT. J Clin Invest 91:1481, 1993
8. Boumpas DT: Anti-inflammatory and immunosuppressive effects, in Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med 119:1198-1208, 1993
9. Beale KM: Azathioprine for the treatment of immune-mediated diseases of dogs and cats. JAVMA 192:1316-1318, 1988
10. Stanton ME, Leendre AE: Effects of cyclophosphamide in dogs and cats. JAVMA 188:1319-1322, 1986
11. Rhodes KH, Shoulberg N: Chlorambucil: Effective therapeutic options for the treatment of feline immune-mediated dermatoses. Feline Pract 20:5-8, 1992
12. Ogilvie GK, Felsburg PJ, Harris CW: Effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response. Vet Immunol Immunopathol, 18:119-127, 1988
13. Rosenkrantz WS, Griffin CE, Barr RJ: Clinical evaluation of cyclosporine in animal models with cutaneous immune-mediated disease and epitheliotropic lymphoma. JAAHA 25:377-383, 1989
14. Halloran PE, Madrena J: The mechanism of action of cyclosporine: A perspective for the 90's. Clin Biochem 24:3-7, 1991
15. Madanes A, Farber M: Danazol. Ann Intern Med 96:625-630, 1982
16. West SG, Johnson SC: Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 108:703-706, 1988
17. Bloom JC, Meunier LD, Thiem PA, et al: Use of danazol for the treatment of corticosteroid-resistant immune-mediated thrombocytopenia in a dog. JAVMA 194:76-78, 1989
18. Ahan YS, Harrington WJ, Mylvaganam R, et al: Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 102:298-310, 1985
19. Holloway SA, Meyer DJ, Mannella C: Prednisolone and danazol for treatment of immune-mediated anemia, thrombocytopenia, and ineffective erythroid regeneration in a dog. JAVMA 197:1045-1048, 1990
20. Bloom JC, Thiem PA, Halper LK, et al: The effect of longterm treatment with auranofin and gold sodium thiomalate on immune function in the dog. J Rheumatol 15:409-417, 1988
21. Serra DA, White SD: Oral chrysotherapy with auranofin in dogs. JAVMA 194:1327-1330, 1989
22. Bussel JB, Cunningham-Rundles C: Intravenous gamma globulin in the treatment of humoral immunodeficiency disease and autoimmune hematologic disease. Rational Drug Therapy 18:1-7, 1984
23. Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 326:107-116, 1992
24. Scott-Moncrieff JC, Reagan WJ, Glickman LT, et al: Treatment of immune mediated hemolytic anemia in dogs with intravenous human immunoglobulin. Proceedings of the Eleventh ACVIM Forum, 1993, p 941 (abstr)
25. Klausner JS, Poffenbarger EM, Matus RE: Therapeutic hemapheresis, in Kirk RW (ed): Current Veterinary Therapy IX, Small Animal Practice, Kirk RW, Philadelphia, WB Saunders, 1986
26. Matus RE, Gordon BR, Leifer CE, et al: Plasmapheresis in five dogs with systemic immune-mediated disease. JAVMA 187:595-599, 1985
27. Matus RE, Schrader LA, Leifer CE, et al: Plasmapheresis as adjuvant therapy for autoimmune hemolytic anemia in two dogs. JAVMA 186:691-693, 1985
28. Strom TE, Kelley VE: Toward more selective therapies to block undesired immune responses. Kidney Int 35:1026-1033, 1989
29. Wofsy D: Strategies for treating autoimmune disease with monoclonal antibodies. High-tech Med (special issue), West J Med 143:804-809, 1985
30. Welsh KI: New strategies in immunosuppression. Pediatr Nephrol 5:622-629, 1991
31. Roitt IM, Cooke A: Manipulation of idiotype networks in autoimmunity. Ciba Found Symp 129:209-222, 1987
32. Hahn BH: Suppression of autoimmune diseases with anti-idiotypic antibodies: Murine lupus nephritis as a model. Springer Semin Immunopathol 7:25-34, 1984
33. Burkholder WJ, Swecker WS: Nutritional influences on immunity. Semin Vet Med Surg (Small Anim), 5:154-166, 1990
34. Fernandes G, Yunis EJ, Miranda M, et al: Nutritional inhibition of genetically determined renal disease and autoimmunity with prolongation of life in kd/kd mice. Proc Natl Acad Sci 75:2888-2892, 1978
35. Schopfer K, Douglas SD: Neutrophil function in children with kwashiorkor. J Lab Clin Med 88:450-461, 1976
36. Haller L, Zubler RH, Lambert PH: Plasma levels of complement and complement haemolytic activity in protein-energy malnutrition. Clin Exp Immunol 34:248-252, 1978
37. Kinsella JE, Lokesh B, Broughton S, et al: Dietary polyunsaturated fatty acids and eicosanoids: Potential effects on the modulation of inflammatory and immune cells: An overview. Nutrition 6:24-44, 1990
38. Kelley VE, Ferretti A, Izui S, et al: A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites and suppresses lupus in MRL-Ipr mice. J Immunol 134:1914-1919, 1985
39. Kremer JM, Lawrence DA, Jubiz W, et al: Dietary fish oil and olive oil in patients with rheumatoid arthritis. Arthritis Rheum 33:810-820, 1990
40. Halloran PF: Molecular mechanisms of new immunosuppressants. Clin Transplant 10:118-123, 1996
41. Morris RE: Mechanisms of action of new immunosuppressive drugs. Ther Drug Monit 17:564-569, 1995
42. Lake KD, Canafax DM: Important interactions of drugs with immunosuppressive agents used in transplant recipients. J Antimicrobial Chemother 36:11-22, 1995 (suppl B)
43. Cramer DV: Brequinar sodium. Pediatr Nephrol 9:S52-55, 1995 (suppl)